Titan Pharmaceuticals Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Titan Pharmaceuticals stock.
View analyst ratings for Titan Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Titan Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Titan Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Titan Pharmaceuticals saw a decline in short interest during the month of May. As of May 28th, there was short interest totaling 679,500 shares, a decline of 24.0% from the May 13th total of 894,200 shares. Based on an average trading volume of 327,800 shares, the short-interest ratio is currently 2.1 days. Currently, 6.9% of the shares of the stock are sold short.
View Titan Pharmaceuticals' Short Interest.

Titan Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Titan Pharmaceuticals.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its quarterly earnings data on Monday, May, 17th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $0.68 million for the quarter. Titan Pharmaceuticals had a negative net margin of 348.18% and a negative trailing twelve-month return on equity of 189.49%.
View Titan Pharmaceuticals' earnings history.

Titan Pharmaceuticals' stock was trading at $7.3350 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TTNP shares have decreased by 66.3% and is now trading at $2.47.
View which stocks have been most impacted by COVID-19.

Shares of Titan Pharmaceuticals reverse split on the morning of Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of Titan Pharmaceuticals stock prior to the reverse split would have 3 shares after the split.

1 brokers have issued twelve-month price objectives for Titan Pharmaceuticals' shares. Their forecasts range from $11.00 to $11.00. On average, they expect Titan Pharmaceuticals' stock price to reach $11.00 in the next year. This suggests a possible upside of 345.3% from the stock's current price.
View analysts' price targets for Titan Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Titan Pharmaceuticals include Cidara Therapeutics (CDTX), Dyadic International (DYAI), Protalix BioTherapeutics (PLX), PolarityTE (PTE), BioCardia (BCDA), Allena Pharmaceuticals (ALNA), aTyr Pharma (LIFE), Genetic Technologies (GENE), Kiromic BioPharma (KRBP), Organovo (ONVO), Windtree Therapeutics (WINT), Idera Pharmaceuticals (IDRA), Brickell Biotech (BBI), Microbot Medical (MBOT) and Enzon Pharmaceuticals (ENZN).
View all of TTNP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), Cannabics Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI).

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

Titan Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include GSA Capital Partners LLP (0.40%), UBS Group AG (0.24%), Credit Suisse AG (0.24%), Bank of New York Mellon Corp (0.18%) and Millennium Management LLC (0.17%).
View institutional ownership trends for Titan Pharmaceuticals.

TTNP stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Credit Suisse AG, Bank of New York Mellon Corp, UBS Group AG, and Millennium Management LLC.
View insider buying and selling activity for Titan Pharmaceuticals or or view top insider-buying stocks.

Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TTNP stock can currently be purchased for approximately $2.47.

Titan Pharmaceuticals has a market capitalization of $24.36 million and generates $4.84 million in revenue each year.

Titan Pharmaceuticals employs 12 workers across the globe.

The official website for Titan Pharmaceuticals is www.titanpharm.com.

Titan Pharmaceuticals is headquartered at 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080.

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected]